Abstract
Bacterial keratitis is a leading cause of visual impairment worldwide. However, the natural history of treated bacterial keratitis has not been well characterized. We performed a secondary analysis of the Steroids for Corneal Ulcers Trial (SCUT; clinicaltrials.gov #NCT00324168) to better characterize the rate of visual acuity improvement after successful antimicrobial treatment.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Anti-Bacterial Agents / therapeutic use
-
Aza Compounds / therapeutic use
-
Corneal Ulcer / drug therapy*
-
Corneal Ulcer / microbiology
-
Corneal Ulcer / physiopathology
-
Eye Infections, Bacterial / drug therapy*
-
Eye Infections, Bacterial / microbiology
-
Eye Infections, Bacterial / physiopathology
-
Female
-
Fluoroquinolones
-
Glucocorticoids / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Moxifloxacin
-
Prednisolone / analogs & derivatives*
-
Prednisolone / therapeutic use
-
Quinolines / therapeutic use
-
Recovery of Function / physiology*
-
Visual Acuity / physiology*
Substances
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Glucocorticoids
-
Quinolines
-
prednisolone phosphate
-
Prednisolone
-
Moxifloxacin
Associated data
-
ClinicalTrials.gov/NCT00324168